Biological Control of Alfalfa Blotch Leafminer (Diptera: Agromyzidae) in Ontario: Status and Ecology of Parasitoids (Hymenoptera: Braconidae, Eulophidae) 20 Years After Introduction

Two European parasitoid species were released in Ontario during the late 1970\u27s to control the alfalfa blotch leafminer, Agromyza frontella (Rondani) (Diptera: Agromyzidae). One of these, Dacnusa dryas (Nixon) (Hymenoptera: Braconidae), rapidly became established and the other, Chrysocharis liriomyzae (= C. punctifacies) (Delucchi) (Hymenoptera: Eulophidae) was never recovered in Ontario. In 1999, we found both D. dryas and C. liriomyzae parasitizing first-generation A. frontella in Ontario in 1999. The combined parasitism rate for both species as revealed by larval dissections was 97.5% by the end of the first A. frontella generation. Of the adult parasitoids reared, 86% were D. dryas and 14% were C. liriomyzae. Most parasitized larvae contained a single unencapsulated (i.e., healthy) larva, along with one or more encapsulated eggs. No larvae were encapsulated, but the overall egg encapsulation rate was 47%. By the end of the first A. frontella generation, 86% of parasitized hosts contained at least one unencapsulated parasitoid and could therefore produce an adult parasitoid, and 12% of parasitized hosts escaped parasitism by containing only encapsulated parasitoids. The sex ratio of D. dryas was even at emergence, but strongly female-biased in sweep samples from the field. Egg loads of D. dryas females were all greater than zero and as high in the field as our highest laboratory estimates, suggesting that egg availability does not limit fitness under the conditions that we observed in the field

DNA damage at the dawn of micro-RNA pathway impairment in pulmonary arterial hypertension: DOI: 10.14800/rd.810

Over the last years, small non-coding microRNAs (miRNAs) have emerged as central actors of PAH etiology. Strong miRNA expression disorders occur in lungs as well as in right ventricle (RV) of PAH patients, which respectively lead to vascular remodeling of the distal pulmonary arteries and to RV failure. On the other hand, our understanding of PAH physiopathology has recently increased with the implication of DNA damage and DNA damage response (DDR) in this disease. Interestingly, DDR was described as a regulator of miRNA processing in both healthy and pathological conditions. In this review, we will first summarize miRNA expression impaired in lung and RV of PAH patients, then we will provide evidence that DDR could be at origin of miRNA pathway defects observed in pulmonary hypertension

Mitochondrial HSP90 Accumulation Promotes Vascular Remodeling in Pulmonary Arterial Hypertension

Rationale: Pulmonary arterial hypertension (PAH) is a vascular remodeling disease with a poor prognosis and limited therapeutic option. Although the mechanisms contributing to vascular remodeling in PAH are still unclear, several features, including hyper-proliferation and resistance to apoptosis of pulmonary artery smooth muscle cells (PASMCs), have led to the emergence of the cancer-like concept. The molecular chaperone heat shock protein 90 (HSP90) is directly associated with malignant growth and proliferation under stress conditions. In addition to be highly expressed in the cytosol, HSP90 exists in a subcellular pool compartmentalized in the mitochondria (mtHSP90) of tumor cells, but not in normal cells, where it promotes cell survival. Objectives: We hypothesized that mtHSP90 in PAH-PASMCs represents a protective mechanism against stress promoting their proliferation and resistance to apoptosis. Measurements and Main Results: We demonstrated that in response to stress HSP90 preferentially accumulates in PAH-PASMC mitochondria (dual immunostaining, immunoblot and immunogold electron microscopy) to ensure cell survival by preserving mitochondrial DNA integrity and bioenergetics functions (Seahorse). Whereas cytosolic HSP90 inhibition displays a lack of absolute specificity for PAH-PASMCs, Gamitrinib, a specific mtHSP90 inhibitor decreased mitochondrial DNA content and repair capacity and bioenergetics functions, thus repressing PAH-PASMC proliferation (Ki67 labeling) and resistance to apoptosis (Annexin V assay) without affecting control cells. In vivo, Gamitrinib improves PAH in two experimental rat models (monocrotaline and Fawn-Hooded rat). Conclusions: Our data show for the first time that accumulation of mtHSP90 is a feature of PAH-PASMCs and key regulator of mitochondrial homeostasis contributing to vascular remodeling in PAH

Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension

International audienceBackground Mutations in the KCNK3 gene have been identified in some patients suffering from heritable pulmonary arterial hypertension (PAH). KCNK3 encodes an outward rectifier K+ channel, and each identified mutation leads to a loss of function. However, the pathophysiological role of potassium channel subfamily K member 3 (KCNK3) in PAH is unclear. We hypothesized that loss of function of KCNK3 is a hallmark of idiopathic and heritable PAH and contributes to dysfunction of pulmonary artery smooth muscle cells and pulmonary artery endothelial cells, leading to pulmonary artery remodeling: consequently, restoring KCNK3 function could alleviate experimental pulmonary hypertension (PH). Methods and Results We demonstrated that KCNK3 expression and function were reduced in human PAH and in monocrotaline-induced PH in rats. Using a patch-clamp technique in freshly isolated (not cultured) pulmonary artery smooth muscle cells and pulmonary artery endothelial cells, we found that KCNK3 current decreased progressively during the development of monocrotaline-induced PH and correlated with plasma-membrane depolarization. We demonstrated that KCNK3 modulated pulmonary arterial tone. Long-term inhibition of KCNK3 in rats induced distal neomuscularization and early hemodynamic signs of PH, which were related to exaggerated proliferation of pulmonary artery endothelial cells, pulmonary artery smooth muscle cell, adventitial fibroblasts, and pulmonary and systemic inflammation. Lastly, in vivo pharmacological activation of KCNK3 significantly reversed monocrotaline-induced PH in rats. Conclusions In PAH and experimental PH, KCNK3 expression and activity are strongly reduced in pulmonary artery smooth muscle cells and endothelial cells. KCNK3 inhibition promoted increased proliferation, vasoconstriction, and inflammation. In vivo pharmacological activation of KCNK3 alleviated monocrotaline-induced PH, thus demonstrating that loss of KCNK3 is a key event in PAH pathogenesis and thus could be therapeutically targeted